ArticleMolecular & cellular proteomics : MCP2012
Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis.
Article in Molecular & cellular proteomics : MCP, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Identification of potential transcriptomic markers in developing ankylosing spondylitis: a meta-analysis of gene expression profiles.BioMed research international · 2015Pooled it
- Metabolomics: A Viable Approach to Understand the Pathogenesis of Reactive ArthritisEndocrine, metabolic & immune disorders drug targets · 2026Review
- Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis.International journal of molecular sciences · 2025Article
- Metabolomics in spondylarthritis.BMC rheumatology · 2025Article
- A role for vessel-associated extracellular matrix proteins in multiple sclerosis pathology.Brain pathology (Zurich, Switzerland) · 2024Article
- The function of the inter-alpha-trypsin inhibitors in the development of disease.Frontiers in medicine · 2024Review
- Decoding ferroptosis: transforming orthopedic disease management.Frontiers in pharmacology · 2024Review
- Gas Chromatography-Mass Spectrometry Reveals Stage-Specific Metabolic Signatures of Ankylosing Spondylitis.Metabolites · 2023Article
- Quantitative proteomic screening uncovers candidate diagnostic and monitoring serum biomarkers of ankylosing spondylitis.Arthritis research & therapy · 2023Article
- Large-Scale Genetic Correlation Analysis between Spondyloarthritis and Human Blood Metabolites.Journal of clinical medicine · 2023Article
- No evidence of a genetic causal relationship between ankylosing spondylitis and iron homeostasis: A two-sample Mendelian randomization study.Frontiers in nutrition · 2023Article
- Untargeted Lipidomics Reveals Characteristic Biomarkers in Patients with Ankylosing Spondylitis Disease.Biomedicines · 2022Article
- Mass spectrometry-based proteomics identify novel serum osteoarthritis biomarkers.Arthritis research & therapy · 2022Article
- Cytoskeletal protein degradation in brain death donor kidneys associates with adverse posttransplant outcomes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Review
- Metabolomic analysis in spondyloarthritis: A systematic review.Frontiers in microbiology · 2022Review
- Ferroptosis in inflammatory arthritis: A promising future.Frontiers in immunology · 2022Review
- p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation.Cell reports · 2021Article
- Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis.Clinical rheumatology · 2020Article
- Biomarker development for axial spondyloarthritis.Nature reviews. Rheumatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Ankylosing Spondylitis (AS) is a common inflammatory rheumatic disease with a predilection for the axial skeleton, affecting 0.2% of the population. Current diagnostic criteria rely on a composite of clinical and radiological changes, with a mean time to diagnosis of 5 to 10 years. In this study we employed nano liquid-chromatography mass spectrometry analysis to detect and quantify proteins and small compounds including endogenous peptides and metabolites in serum from 18 AS patients and nine healthy individuals. We identified a total of 316 proteins in serum, of which 22 showed significant up- or down-regulation (p < 0.05) in AS patients. Receiver operating characteristic analysis of combined levels of serum amyloid P component and inter-α-trypsin inhibitor heavy chain 1 revealed high diagnostic value for Ankylosing Spondylitis (area under the curve = 0.98). We also depleted individual sera of proteins to analyze endogenous peptides and metabolic compounds. We detected more than 7000 molecular features in patients and healthy individuals. Quantitative MS analysis revealed compound profiles that correlate with the clinical assessment of disease activity. One molecular feature identified as a Vitamin D3 metabolite-(23S,25R)-25-hydroxyvitamin D3 26,23-peroxylactone-was down-regulated in AS. The ratio of this vitamin D metabolite versus vitamin D binding protein serum levels was also altered in AS as compared with controls. These changes may contribute to pathological skeletal changes in AS. Our study is the first example of an integration of proteomic and metabolomic techniques to find new biomarker candidates for the diagnosis of Ankylosing Spondylitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.